Prostate cancer and PARP inhibitors: progress and challenges

Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or somatic alterations of DNA-damage response pathway genes are found in a substantial number...

Descripción completa

Detalles Bibliográficos
Autores principales: Teyssonneau, Diego, Margot, Henri, Cabart, Mathilde, Anonnay, Mylène, Sargos, Paul, Vuong, Nam-Son, Soubeyran, Isabelle, Sevenet, Nicolas, Roubaud, Guilhem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008655/
https://www.ncbi.nlm.nih.gov/pubmed/33781305
http://dx.doi.org/10.1186/s13045-021-01061-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008655/
https://www.ncbi.nlm.nih.gov/pubmed/33781305
http://dx.doi.org/10.1186/s13045-021-01061-x

Ejemplares similares